AU695366B2 - Use of melatonin for treating patients suffering from drug addiction - Google Patents

Use of melatonin for treating patients suffering from drug addiction

Info

Publication number
AU695366B2
AU695366B2 AU44574/96A AU4457496A AU695366B2 AU 695366 B2 AU695366 B2 AU 695366B2 AU 44574/96 A AU44574/96 A AU 44574/96A AU 4457496 A AU4457496 A AU 4457496A AU 695366 B2 AU695366 B2 AU 695366B2
Authority
AU
Australia
Prior art keywords
melatonin
patient
benzodiazepine drug
benzodiazepine
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU44574/96A
Other languages
English (en)
Other versions
AU4457496A (en
Inventor
Nava Zisapel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurim Pharmaceuticals 1991 Ltd
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of AU4457496A publication Critical patent/AU4457496A/en
Application granted granted Critical
Publication of AU695366B2 publication Critical patent/AU695366B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU44574/96A 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction Expired AU695366B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
US381535 1995-02-01
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies
EP95303853 1995-06-06
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (2)

Publication Number Publication Date
AU4457496A AU4457496A (en) 1996-08-21
AU695366B2 true AU695366B2 (en) 1998-08-13

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44574/96A Expired AU695366B2 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Country Status (22)

Country Link
JP (1) JP4516159B2 (cs)
CN (1) CN1083263C (cs)
AT (1) AT408188B (cs)
AU (1) AU695366B2 (cs)
BG (1) BG62876B1 (cs)
BR (1) BR9607169A (cs)
CZ (1) CZ291349B6 (cs)
DK (1) DK176081B1 (cs)
EE (1) EE03384B1 (cs)
FI (1) FI119586B (cs)
IS (1) IS1980B (cs)
LU (1) LU90118B1 (cs)
LV (1) LV11940B (cs)
MD (1) MD1716C2 (cs)
NO (1) NO312814B1 (cs)
NZ (1) NZ298878A (cs)
PL (1) PL183148B1 (cs)
SI (1) SI9620022A (cs)
SK (1) SK284521B6 (cs)
TR (1) TR199700723T1 (cs)
TW (1) TW483757B (cs)
WO (1) WO1996023496A1 (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150190A0 (en) 2000-01-05 2002-12-01 Neurim Pharma 1991 Method and formulation for treating resistance to antihypertensives and related conditions
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL330095A (en) 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
IL266159B2 (en) 2012-12-18 2024-07-01 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
DK3337462T3 (da) * 2016-10-31 2020-10-12 Neurim Pharma 1991 Melatonin-minitabletter og fremgangsmåde til fremstilling heraf

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229490T2 (de) * 1991-05-09 2000-02-17 Neurim Pharmaceuticals (1991) Ltd., Tel Aviv Melatonin enthaltende Arzneimittel
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Also Published As

Publication number Publication date
PL183148B1 (pl) 2002-05-31
CZ240597A3 (cs) 1998-01-14
BR9607169A (pt) 1997-11-11
MD1716C2 (ro) 2002-02-28
PL321630A1 (en) 1997-12-08
EE9700166A (et) 1998-02-16
ATA901396A (de) 2001-02-15
JP4516159B2 (ja) 2010-08-04
SK284521B6 (sk) 2005-05-05
FI973185A0 (fi) 1997-07-31
MD970254A (en) 1999-05-31
SI9620022A (sl) 1998-10-31
TW483757B (en) 2002-04-21
TR199700723T1 (xx) 1998-02-21
EE03384B1 (et) 2001-04-16
NZ298878A (en) 1999-05-28
IS1980B (is) 2005-01-14
DK89697A (da) 1997-07-30
MX9705856A (es) 1998-07-31
AU4457496A (en) 1996-08-21
FI119586B (fi) 2009-01-15
SK103097A3 (en) 1998-01-14
JPH10513177A (ja) 1998-12-15
CN1083263C (zh) 2002-04-24
BG101803A (en) 1998-04-30
NO973531L (no) 1997-09-30
WO1996023496A1 (en) 1996-08-08
CZ291349B6 (cs) 2003-02-12
CN1172431A (zh) 1998-02-04
LV11940A (lv) 1998-01-20
AT408188B (de) 2001-09-25
MD1716B2 (en) 2001-08-31
LV11940B (en) 1998-05-20
FI973185L (fi) 1997-09-30
DK176081B1 (da) 2006-04-18
IS4532A (is) 1997-07-25
NO973531D0 (no) 1997-07-31
NO312814B1 (no) 2002-07-08
BG62876B1 (bg) 2000-10-31
LU90118B1 (fr) 1997-11-13

Similar Documents

Publication Publication Date Title
EP0724878B1 (en) Use of melatonin for treating patients suffering from drug dependencies
US11241429B2 (en) Method of treating metabolic disorders and depression with dopamine receptor agonists
Blomqvist et al. Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol
Garfinkel et al. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs
Söderpalm et al. Anticonflict and rotarod impairing effects of alprazolam and diazepam in rat after acute and subchronic administration
Slatkin et al. Donepezil in the treatment of opioid-induced sedation: report of six cases
WO1996023496A1 (en) Use of melatonin for treating patients suffering from drug addiction
KR101000624B1 (ko) 멜라토닌을 포함하는 약제학적 제제
US6344487B1 (en) Treatment of insomnia
Buydens‐Branchey et al. Craving for cocaine in addicted users: Role of serotonergic mechanisms
JPH10513177A5 (cs)
CA2211839C (en) Use of melatonin for treating patients suffering from drug addiction
Zisapel Development of a melatonin‐based formulation for the treatment of insomnia in the elderly
HK1001218B (en) Use of melatonin for treating patients suffering from drug dependencies
Monteleone et al. Lack of effect of short-term fluoxetine administration on nighttime plasma melatonin levels in healthy subjects
MXPA97005856A (en) Use of melatonine in the manufacture of unmedicament to deal with addiction to dro
FUNCTIONING SLEEP MORE!
Conroy et al. Sleep and substance use and abuse
Bourin et al. New approaches to panic disorder
Wasielewski Attenuation of alcohol-induced circadian phase-shifts using melatonin and vitamin B12